# A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

> **NCT05734105** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Deciphera Pharmaceuticals, LLC** · enrollment: 54 (estimated)

## Conditions studied

- GIST

## Interventions

- **DRUG:** Ripretinib
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT05734105
- **Lead sponsor:** Deciphera Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-13
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05734105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05734105, "A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05734105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*